Nicolas Poirier

Chief Executive Officer at OSE IMMUNOTHERAPEUTICS

Net worth: 1 M $ as of 2024-03-30

42 year

Consumer Services

Health Technology

Profile

Nicolas Poirier is currently the Chief Executive Officer & Director at OSE Immunotherapeutics SA since 2022.
Previously, he worked as a Project Manager at Effimune SA. Dr. Poirier has a graduate degree from the University of Nantes and Louis Pasteur University, and an undergraduate degree from the Centre d'Etudes Supérieures de Techniques Industrielles.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
OSE IMMUNOTHERAPEUTICS SA 0.89%	2022-12-30	192,802 ( 0.89% )	1 M $	2024-03-30

Nicolas Poirier active positions

Companies	Position	Start
OSE IMMUNOTHERAPEUTICS	Chief Executive Officer	2022-10-06

All active positions of Nicolas Poirier

Former positions of Nicolas Poirier

Companies	Position	End
Effimune SA Effimune SA BiotechnologyHealth Technology Effimune SA engages in the research and development of drugs for transplantation and immune-mediated diseases. It covers the identification of novel therapeutic targets, the development of therapeutics, pilot manufacturing, set-up of animal models, pre-clinical and early clinical development. The company was founded by Maryvonne Hiance, Bernard Vanhove and Sophie Brouard in 2007 and is headquartered in Nantes, France.	Corporate Officer/Principal	-

See the detail of Nicolas Poirier's experience

Training of Nicolas Poirier

University of Nantes	Graduate Degree
Centre d'Etudes Supérieures de Techniques Industrielles	Undergraduate Degree
Louis Pasteur University	Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Nicolas Poirier's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
OSE IMMUNOTHERAPEUTICS	Health Technology

Private companies	1
Effimune SA Effimune SA BiotechnologyHealth Technology Effimune SA engages in the research and development of drugs for transplantation and immune-mediated diseases. It covers the identification of novel therapeutic targets, the development of therapeutics, pilot manufacturing, set-up of animal models, pre-clinical and early clinical development. The company was founded by Maryvonne Hiance, Bernard Vanhove and Sophie Brouard in 2007 and is headquartered in Nantes, France.	Health Technology